Monday, March 03, 2025 | 09:25 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Lupin receives USFDA tentative approval for Empagliflozin and Linagliptin Tablets

Image

Capital Market
Lupin has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 23 2020 | 6:17 PM IST

Explore News